Gilead Expands its May 2020 Collaboration with Arcus Biosciences to Include Inflammatory Research Programs
Shots:
- The companies expand their May 2020 collaboration to include inflammatory disease therapies. Arcus will receive $35M up front, ~ $420M in options & milestones along with royalties for each of the first 2 programs if Gilead exercises its option
- Arcus will initiate research programs against up to four inflammatory disease targets chosen with Gilead. Gilead to get an early option to exclusively license each program at 2 separate, prespecified points in time
- The parties will get rights to co-develop & co-commercialize in the US for optioned programs along with sharing global development costs & profits for other options exercised by Gilead. The new collaboration will combine Arcus’ research expertise with Gilead’s clinical experience to advance new therapies
Ref: Gilead | Image: Gilead
Related News:- Ono Entered into a Collaboration and Option Agreement with Cue Biopharma for CUE-401 to Treat Autoimmune and Inflammatory Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
